Human stem cells have great potential for finding restoring damaged tissues throughout the body and speeding the drug discovery process. We are developing a combined approach of both the cells needed to restore the damaged area and using these cells in a Petri dish to discover new compounds to treat diseases such as Alzheimer’s disease.
Through collaborations with others, including scientists at Georgia Tech and Emory, we are developing therapies and drug discovery tools. Animal stem cells and cloning benefits are far reaching, from treating race horse bone and cartilage damage to pig stem cells to treat diabetes in humans. Our platform technology will launch genetic progress in agricultural, veterinary and biomedical industries.
► >RBC: The Regenerative Bioscience Center at UGA, links researchers and resources collaborating in a wide range of disciplines to develop new cures for the devastating diseases that touch all of our lives. The RBC is a collaboration geared toward identifying regenerative solutions for numerous medical conditions that affect both animals and people. Director Dr. Steven Stice
► >EBICS: Emergent Behaviors of Integrated Cellular Systems. A National Science Foundation Science and Technology Center, dedicated to creating a new scientific discipline for building living, multi-cellular machines that solve real world problems in health, security, and the environment. EBICS has a fundamental understanding of interactions between cells and their environment, their control by biochemical and mechanical cues, and the coordinated behavior of functional cells in a machine. Faculty Dr. Steven Stice
► >Georgia Research Alliance: (GRA) expands research and commercialization capacity in Georgia’s universities to launch new companies, create high-value jobs and transform lives. Georgia Research Alliance Eminent Scholar Dr. Steven Stice
► >Regenerative Engineering and Medicine (REM) A research center focused on endogenous repair or how the body can harness its own potential to heal or regenerate. REM is a joint collaboration between Emory University and Georgia Tech. Director Dr. Steven Stice
► Finding new treatments for degenerative diseases such Parkinson’s, Alzheimer’s and Multiple Sclerosis Continued focus on neural injuries — spinal cord and head trauma, as well as, treating cardiovascular diseases (heart and blood vessel repair) through stem cell technologies.
► Development of cell-based assays to support high-throughput chemical and compound screening, ultimately leading to better reproducibility and predictability resulting in more effective drug therapies.
► Animal stem cells and cloning animal agriculture, veterinary and biomedicine applications.
► The use of stem cells in fracture healing and complex bone injury.
► Toxicology, with particular emphasis on environmental and health risks, and how emerging new therapeutic interventions could be translated into preventive strategies, and improved scientific basis for risk assessment.
►New neural stem cells technology developed in the lab were transferred to a commercial entity, Aruna biomedical. This is the first commercialized product derived from human embryonic stem cell using federally approved stem cell lines.
►Established a collaborative work on developing a mini spinal cord that can be used in conjunction with the walking biobots. The process uses mESC derived neurons made to form a spinal cord that will be placed adjacent to the walking biobot.
►Produced neurons that have neural functions
►Collaboration effort with the US Navy to use our neural cells as biosensors for environmental toxins
►Animal stem cells and cloning animal agriculture, veterinary and biomedicine applications
►We have vascular stem cells that have characteristics that may make them suitable for transplantation
►Collaboration with Aruna BioMedical using stem cells for neural research and drug discovery
►Developed a method to test new compounds for Alzheimer’s disease using our neural stem cell
Dr. Steven Stice awarded the highest scholastic faculty award; The D.W. Brooks Distinguished Professorship, is also a Georgia Research Alliance Eminent Scholar endowed chair, and Director of the Regenerative Bioscience Center at The University of Georgia (UGA). He has over 20 years of research and development experience in biotechnology and is a co-founder of five biotechnology companies, including ArunA Biomedical and SciStem, which he currently serves as Chief Scientific Officer. ArunA was the first company to commercialize a product derived from human pluripotent stem cells, and the company has developed stem cells that were used to facilitate approval of Pfizer’s current cognitive enhancing pharmaceuticals.
Prior to joining UGA, Dr. Stice was the co-founder and served as both CSO and CEO of Advanced Cell Technology, the only US company currently in human clinical trials using human pluripotent stem cells. Additionally he co-founded startups; Prolinia and Cytogenesis which later merged with what is now, ViaCyte.
Dr. Stice has led industry and academic research teams in the area of pluripotent stem cells for over 20 years. In 2001, his labs were first in deriving one set of the original human embryonic stem cell lines in collaboration with BresaGen, Inc. (BG01, 02 and 03), and these lines were placed on the first NIH human ESC registry. Dr. Stice produced the first cloned rabbit in 1987 and the first cloned transgenic calves in 1998 (George and Charlie). In 1997 his group produced the first genetically modified embryonic stem cell derived pigs and cattle. His laboratories were one of only five NIH sponsored sites for training NIH investigators on the propagation, differentiation and use of hESC over a six year period.
Currently, the Stice lab is developing novel therapies and new technologies for drug screening, which could change the lives of those suffering with Parkinson’s and Alzheimer's. Stice’s research has led to publications in Science and Nature journals, national news coverage (CBS, NBC, ABC and CNN) and the first US patents on cloning animals and cattle stem cells which was featured in the Wall Street Journal.
Here's what's on display in Steve Stice's office: There's a sunlit photo of his family on a fishing expedition..,a fantasy baseball league trophy, and pale carved jade animals (a gift from his father) that are meant to represent the world of cloning possibilities, from the realistic (a mouse) to the wildly improbable (a snarling tiger). Here’s what is not on display: the trappings of scientific celebrity. Blum, Georgia Magazine
Dr. Steve Stice is a Georgia Research Alliance Eminent Scholar endowed chair, Professor and Director of the Regenerative Bioscience Center at The University of Georgia and serves as Chief Scientific Officer for ArunA Biomedical Inc. Dr. Stice co-founded five biotechnology companies, including Advanced Cell Technology, and CytoGenesis, Inc., which was later purchased by BresaGen.
Dr. Stice helped BresaGen develop four of the human embryonic stem cell lines approved for NIH funding. He produced the first cloned rabbit in 1987 and the first cloned transgenic calves, George and Charlie, in 1988. In 1997, he produced the first genetically modified embryonic stem cell derived pigs and cattle. Dr. Stice holds fourteen patents with six pending, all dealing with stem cells or cloning.
In 2001, he announced a breakthrough in the cloning process and the first cloned animal (calf) from an animal that was dead for 48 hours.
Throughout his career, he has published and lectured on cloning and stem cell technologies. His research focuses on developing innovative animal cloning and stem cell technologies. Dr. Stice was named one of the 100 Most Influential Georgians in 2002 by Georgia Trend magazine. In 2000, he was named one of the top forty entrepreneurs under forty years old in Georgia, and he received the AGR grand president’s award for leadership in agriculture and the Outstanding Young Alumni Award from the University of Illinois.
Dr. Stice received a B.S. degree in Agricultural Science from the University of Illinois in 1983, an M.S. degree in 1985 from Iowa State University, and a Ph.D. in 1989 from the University of Massachusetts in Amherst. Steve Stice CURRICULUM VITAE